Anavex Life Sciences Corp reports results for the quarter ended December 31 - Earnings Summary

• Anavex Life Sciences Corp AVXL.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -11 cents. The lone analyst forecast for the quarter was for a loss of 17 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Anavex Life Sciences Corp's reported EPS for the quarter was a loss of 14 cents​.

• Anavex Life Sciences Corp shares had fallen by 22.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 10.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Anavex Life Sciences Corp is $41.45

This summary was machine generated from LSEG data February 12 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)